Nanomedicines: From Bench to Bedside and Beyond
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and te...
Gespeichert in:
| Veröffentlicht in: | The AAPS journal 2016-11, Vol.18 (6), p.1373-1378 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1378 |
|---|---|
| container_issue | 6 |
| container_start_page | 1373 |
| container_title | The AAPS journal |
| container_volume | 18 |
| creator | Havel, Henry Finch, Gregory Strode, Pamela Wolfgang, Marc Zale, Stephen Bobe, Iulian Youssoufian, Hagop Peterson, Matthew Liu, Maggie |
| description | Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. |
| doi_str_mv | 10.1208/s12248-016-9961-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1826739775</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1826739775</sourcerecordid><originalsourceid>FETCH-LOGICAL-p184t-c02bcb0c70ac76578cae74f89f9b79567572cde2567ed8f7acd404595bc3302c3</originalsourceid><addsrcrecordid>eNo1kD1PwzAQhi0kREvhB7CgjCym_szZbFBRQKpggdlybAdSNXaJm6H_Hlct073SPTrd-yB0Q8k9ZUTNM2VMKExojbWuKYYzNKVSEgyC1hN0mfOaEM44pRdowkAowqmaovm7jakPvnNdDPmhWg6pr55CdD_VLpXgc-dDZaMveZ-iv0Lnrd3kcH2aM_S1fP5cvOLVx8vb4nGFt1SJHXaENa4hDoh1UEtQzgYQrdKtbkDLGiQw5wMrKXjVgnVeECG1bBznhDk-Q3fHu9sh_Y4h70zfZRc2GxtDGrOhitXANYAs6O0JHZvSxGyHrrfD3vyXLAA7Arms4ncYzDqNQyzvG0rMwZ452jPFnjnYM8D_AFhMX-w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1826739775</pqid></control><display><type>article</type><title>Nanomedicines: From Bench to Bedside and Beyond</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>PubMed Central</source><creator>Havel, Henry ; Finch, Gregory ; Strode, Pamela ; Wolfgang, Marc ; Zale, Stephen ; Bobe, Iulian ; Youssoufian, Hagop ; Peterson, Matthew ; Liu, Maggie</creator><creatorcontrib>Havel, Henry ; Finch, Gregory ; Strode, Pamela ; Wolfgang, Marc ; Zale, Stephen ; Bobe, Iulian ; Youssoufian, Hagop ; Peterson, Matthew ; Liu, Maggie</creatorcontrib><description>Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients.</description><identifier>EISSN: 1550-7416</identifier><identifier>DOI: 10.1208/s12248-016-9961-7</identifier><identifier>PMID: 27480318</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Animals ; Biochemistry ; Biological Products - therapeutic use ; Biomedical and Life Sciences ; Biomedicine ; Biotechnology ; Drug Approval ; Drug Delivery Systems - trends ; Drug Industry - legislation & jurisprudence ; Drug Industry - trends ; Humans ; Nanomedicine - legislation & jurisprudence ; Nanomedicine - trends ; Nanoparticles - administration & dosage ; Pharmacology/Toxicology ; Pharmacy ; Preparing for the Future ; Review Article ; Theme: Nanotechnology in Complex Drug Products: Learning from the Past</subject><ispartof>The AAPS journal, 2016-11, Vol.18 (6), p.1373-1378</ispartof><rights>American Association of Pharmaceutical Scientists 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><orcidid>0000-0001-7106-8203</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1208/s12248-016-9961-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1208/s12248-016-9961-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27480318$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Havel, Henry</creatorcontrib><creatorcontrib>Finch, Gregory</creatorcontrib><creatorcontrib>Strode, Pamela</creatorcontrib><creatorcontrib>Wolfgang, Marc</creatorcontrib><creatorcontrib>Zale, Stephen</creatorcontrib><creatorcontrib>Bobe, Iulian</creatorcontrib><creatorcontrib>Youssoufian, Hagop</creatorcontrib><creatorcontrib>Peterson, Matthew</creatorcontrib><creatorcontrib>Liu, Maggie</creatorcontrib><title>Nanomedicines: From Bench to Bedside and Beyond</title><title>The AAPS journal</title><addtitle>AAPS J</addtitle><addtitle>AAPS J</addtitle><description>Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients.</description><subject>Animals</subject><subject>Biochemistry</subject><subject>Biological Products - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Drug Approval</subject><subject>Drug Delivery Systems - trends</subject><subject>Drug Industry - legislation & jurisprudence</subject><subject>Drug Industry - trends</subject><subject>Humans</subject><subject>Nanomedicine - legislation & jurisprudence</subject><subject>Nanomedicine - trends</subject><subject>Nanoparticles - administration & dosage</subject><subject>Pharmacology/Toxicology</subject><subject>Pharmacy</subject><subject>Preparing for the Future</subject><subject>Review Article</subject><subject>Theme: Nanotechnology in Complex Drug Products: Learning from the Past</subject><issn>1550-7416</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kD1PwzAQhi0kREvhB7CgjCym_szZbFBRQKpggdlybAdSNXaJm6H_Hlct073SPTrd-yB0Q8k9ZUTNM2VMKExojbWuKYYzNKVSEgyC1hN0mfOaEM44pRdowkAowqmaovm7jakPvnNdDPmhWg6pr55CdD_VLpXgc-dDZaMveZ-iv0Lnrd3kcH2aM_S1fP5cvOLVx8vb4nGFt1SJHXaENa4hDoh1UEtQzgYQrdKtbkDLGiQw5wMrKXjVgnVeECG1bBznhDk-Q3fHu9sh_Y4h70zfZRc2GxtDGrOhitXANYAs6O0JHZvSxGyHrrfD3vyXLAA7Arms4ncYzDqNQyzvG0rMwZ452jPFnjnYM8D_AFhMX-w</recordid><startdate>20161101</startdate><enddate>20161101</enddate><creator>Havel, Henry</creator><creator>Finch, Gregory</creator><creator>Strode, Pamela</creator><creator>Wolfgang, Marc</creator><creator>Zale, Stephen</creator><creator>Bobe, Iulian</creator><creator>Youssoufian, Hagop</creator><creator>Peterson, Matthew</creator><creator>Liu, Maggie</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7106-8203</orcidid></search><sort><creationdate>20161101</creationdate><title>Nanomedicines: From Bench to Bedside and Beyond</title><author>Havel, Henry ; Finch, Gregory ; Strode, Pamela ; Wolfgang, Marc ; Zale, Stephen ; Bobe, Iulian ; Youssoufian, Hagop ; Peterson, Matthew ; Liu, Maggie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p184t-c02bcb0c70ac76578cae74f89f9b79567572cde2567ed8f7acd404595bc3302c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Biochemistry</topic><topic>Biological Products - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Drug Approval</topic><topic>Drug Delivery Systems - trends</topic><topic>Drug Industry - legislation & jurisprudence</topic><topic>Drug Industry - trends</topic><topic>Humans</topic><topic>Nanomedicine - legislation & jurisprudence</topic><topic>Nanomedicine - trends</topic><topic>Nanoparticles - administration & dosage</topic><topic>Pharmacology/Toxicology</topic><topic>Pharmacy</topic><topic>Preparing for the Future</topic><topic>Review Article</topic><topic>Theme: Nanotechnology in Complex Drug Products: Learning from the Past</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Havel, Henry</creatorcontrib><creatorcontrib>Finch, Gregory</creatorcontrib><creatorcontrib>Strode, Pamela</creatorcontrib><creatorcontrib>Wolfgang, Marc</creatorcontrib><creatorcontrib>Zale, Stephen</creatorcontrib><creatorcontrib>Bobe, Iulian</creatorcontrib><creatorcontrib>Youssoufian, Hagop</creatorcontrib><creatorcontrib>Peterson, Matthew</creatorcontrib><creatorcontrib>Liu, Maggie</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>The AAPS journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Havel, Henry</au><au>Finch, Gregory</au><au>Strode, Pamela</au><au>Wolfgang, Marc</au><au>Zale, Stephen</au><au>Bobe, Iulian</au><au>Youssoufian, Hagop</au><au>Peterson, Matthew</au><au>Liu, Maggie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanomedicines: From Bench to Bedside and Beyond</atitle><jtitle>The AAPS journal</jtitle><stitle>AAPS J</stitle><addtitle>AAPS J</addtitle><date>2016-11-01</date><risdate>2016</risdate><volume>18</volume><issue>6</issue><spage>1373</spage><epage>1378</epage><pages>1373-1378</pages><eissn>1550-7416</eissn><abstract>Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>27480318</pmid><doi>10.1208/s12248-016-9961-7</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-7106-8203</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1550-7416 |
| ispartof | The AAPS journal, 2016-11, Vol.18 (6), p.1373-1378 |
| issn | 1550-7416 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1826739775 |
| source | MEDLINE; SpringerLink Journals; PubMed Central |
| subjects | Animals Biochemistry Biological Products - therapeutic use Biomedical and Life Sciences Biomedicine Biotechnology Drug Approval Drug Delivery Systems - trends Drug Industry - legislation & jurisprudence Drug Industry - trends Humans Nanomedicine - legislation & jurisprudence Nanomedicine - trends Nanoparticles - administration & dosage Pharmacology/Toxicology Pharmacy Preparing for the Future Review Article Theme: Nanotechnology in Complex Drug Products: Learning from the Past |
| title | Nanomedicines: From Bench to Bedside and Beyond |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T07%3A42%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanomedicines:%20From%20Bench%20to%20Bedside%20and%20Beyond&rft.jtitle=The%20AAPS%20journal&rft.au=Havel,%20Henry&rft.date=2016-11-01&rft.volume=18&rft.issue=6&rft.spage=1373&rft.epage=1378&rft.pages=1373-1378&rft.eissn=1550-7416&rft_id=info:doi/10.1208/s12248-016-9961-7&rft_dat=%3Cproquest_pubme%3E1826739775%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1826739775&rft_id=info:pmid/27480318&rfr_iscdi=true |